RETHYMIC is a Intramuscular Implant in the Human Prescription Drug category. It is labeled and distributed by Enzyvant Therapeutics Inc.. The primary component is Allogenic Thymocyte-depleted Thymus Tissue-agdc.
| Product ID | 72359-001_8cba898b-a93e-4df5-b541-95142ac58883 |
| NDC | 72359-001 |
| Product Type | Human Prescription Drug |
| Proprietary Name | RETHYMIC |
| Generic Name | Allogenic Thymocyte-depleted Thymus Tissue-agdc |
| Dosage Form | Implant |
| Route of Administration | INTRAMUSCULAR |
| Marketing Start Date | 2021-10-08 |
| Marketing Category | BLA / |
| Application Number | BLA125685 |
| Labeler Name | Enzyvant Therapeutics Inc. |
| Substance Name | ALLOGENIC THYMOCYTE-DEPLETED THYMUS TISSUE-AGDC |
| Active Ingredient Strength | 22000 mm/1 |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2021-10-08 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() RETHYMIC 88715931 not registered Live/Pending |
Enzyvant Therapeutics GmbH 2019-12-05 |
![]() RETHYMIC 88319658 not registered Live/Pending |
Enzyvant Therapeutics GmbH 2019-02-28 |